Comparing Pfizer and Viking Therapeutics: Evaluating the Better Pharmaceutical Investment
Tuesday, 23 April 2024, 13:15
Pfizer: A reliable income stock
Pfizer's shares have taken a hit in the post-pandemic era, recently printing a fresh 52-week low.
Why consider Pfizer as a buy-and-hold investment?
Pfizer's primary appeal arguably lies in its potential as a stable source of passive income.
- Strategy: Pfizer's strength in numbers strategy makes it a less risky big pharma stock.
- Dividend: Pfizer boasts the highest dividend yield among big pharma stocks at 6.4%.
Viking Therapeutics: A promising growth play
Viking Therapeutics recently unveiled mid-stage trial data for VK2735, a potential weight-loss medication.
What's the risk?
There's no guarantee VK2735 will replicate mid-stage trial results in a larger study.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.